# Lanreotide Autogel Treatment of Patients With Congenital Hyperinsulinism of Infancy

> **NCT01070758** · PHASE4 · COMPLETED · sponsor: **Sheba Medical Center** · enrollment: 3 (actual)

## Conditions studied

- Congenital Hyperinsulinism

## Interventions

- **DRUG:** Lanreotide autogel

## Key facts

- **NCT ID:** NCT01070758
- **Lead sponsor:** Sheba Medical Center
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-02
- **Primary completion:** 2015-02
- **Final completion:** 2015-02
- **Target enrollment:** 3 (ACTUAL)
- **Last updated:** 2024-04-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01070758

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01070758, "Lanreotide Autogel Treatment of Patients With Congenital Hyperinsulinism of Infancy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01070758. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*